CN113679658A - Soluble microneedle patch for itching-relieving and anti-allergic treatment of skin and preparation method thereof - Google Patents
Soluble microneedle patch for itching-relieving and anti-allergic treatment of skin and preparation method thereof Download PDFInfo
- Publication number
- CN113679658A CN113679658A CN202111152261.1A CN202111152261A CN113679658A CN 113679658 A CN113679658 A CN 113679658A CN 202111152261 A CN202111152261 A CN 202111152261A CN 113679658 A CN113679658 A CN 113679658A
- Authority
- CN
- China
- Prior art keywords
- needle body
- microneedle patch
- matrix material
- pure water
- body solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Abstract
The invention discloses a microneedle patch for itching-relieving and anti-allergic treatment of skin and a preparation method thereof. The micro-needle patch needle body comprises active medicines, a high-molecular matrix material, an acid-base regulator and pure water. When the soluble microneedle patch disclosed by the invention is applied to an affected part, the base part of the patch is pressed, the needle body gradually releases the medicine, and the effect is achieved, so that the purposes of relieving itching and resisting allergy to mosquito bites of patients are achieved. Compared with transdermal preparation and oral preparation, the preparation has the advantages of low dosage and good effect.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to a soluble microneedle patch for itching-relieving and anti-allergic treatment of skin and a preparation method thereof.
Background
Mosquito bite dermatitis is an acute inflammatory skin disease caused by insect (especially mosquito) bite or poison juice and hair irritation, is a common disease of the summer dermatology department, and mainly has local skin rash and skin pruritus as clinical manifestations. For example, after the mosquito bites the skin, saliva of the mosquito contains a large amount of allergens such as proteins and the like, which cause allergic reactions at the bite part, the allergic reactions can trigger inflammatory reactions, the inflammation part can release a large amount of histamine after the inflammation part is painful, and reactions of a plurality of cells, particularly the allergic reactions and the inflammatory reactions can be influenced. Allergic and inflammatory reactions can lead to increased itching. The insect bite dermatitis affects the daily life and rest of people due to high incidence rate and uncomfortable skin pruritus. On the conventional treatment of insect bite dermatitis, patients with slight symptoms can take antihistamine medicines by local external use of glucocorticoid preparations, external use of calamine lotion and other antipruritic medicines, patients with wide skin damage and serious symptoms can take glucocorticoid medicines for a short time, and patients with severe anaphylaxis can take antibacterial medicines for secondary infected patients. At present, external glucocorticoid creams for treating insect bite dermatitis are common in the market, and have the characteristics of obvious anti-inflammatory effect and poor itching relieving and anti-allergic effects. Oral antihistamines are in large doses. Therefore, the development of a novel efficient topical transdermal drug delivery mode for skin itching-relieving and anti-allergic treatment of mosquito bites is particularly urgent.
Pharmacologically, antihistamines or glucocorticoids are mainly used for the treatment of allergic reactions. The biosoluble microneedle is prepared from a high polymer material with good biocompatibility, can realize high-efficiency micro-dosage transdermal drug delivery, can be dissolved automatically after penetrating into human skin, realizes micro-drug delivery, and can realize the control of release rate according to the screening of different matrix materials and combined matrixes. Compared with other existing transdermal preparations, the transdermal preparation has the advantage of transdermal effect; compared with oral medicines, the Chinese medicinal composition is locally administrated, and the effect can be achieved by a small dose, so that accurate striking is realized.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a soluble microneedle patch for skin itching-relieving and anti-allergic treatment and a preparation method thereof. The microneedle patch can realize transdermal drug delivery for treating local skin allergy caused by mosquito bite, and realize transdermal drug delivery. The biosoluble microneedle patch can safely and effectively deliver drugs through skin, avoids side effects caused by oral administration, has administration efficiency higher than that of a conventional itching-relieving and antiallergic transdermal preparation, and is simple and convenient in preparation method and strong in operability.
In order to achieve the purpose, the invention adopts the following technical scheme: a soluble microneedle patch for skin itching relieving and anti-allergy treatment comprises a substrate and a needle body, wherein the needle body is prepared by mixing an active drug, a polymer matrix material and pure water, and the mass ratio of the active drug to the polymer matrix material to the pure water is 0.01-5:95-99.99: 200-; the substrate is prepared from a high-molecular matrix material.
Further, the active pharmaceutical ingredient is an antihistamine or a glucocorticoid.
Further, the antihistamine is preferably one or more of chlorpheniramine, diphenhydramine, loratadine, cetirizine, chlorpheniramine, flufenamic acid butyl ester, ethoxybenzene willow amine or medically acceptable salts of the antihistamine in any proportion.
Further, the glucocorticoid is preferably one or more of desonide, dexamethasone acetate, chlorhydrine, fluticasone propionate, halometasone paste, halcinonide or medically acceptable salts of the glucocorticoid, which are mixed according to any proportion.
Further, the polymer matrix material is preferably one or more of polyvinylpyrrolidone, polyvinyl alcohol, chitosan, sodium hyaluronate, chondroitin sulfate and modified derivatives of the above materials, mixed at any ratio.
The invention discloses a preparation method of a soluble microneedle patch for skin itching relieving and anti-allergic treatment, which comprises the following steps:
(1) preparing a needle body material: uniformly dispersing active medicine components and a high-molecular matrix material into pure water, wherein the mass ratio of the active medicine to the high-molecular matrix material to the pure water is 0.01-5:95-99.99:200 and 1500, and adjusting the pH to 7.0 +/-0.2 by using an acid-base regulator to obtain a needle body solution;
(2) preparing a needle body: adding the needle body solution prepared in the step (1) into a microneedle mould, completely filling the needle body solution into the gap of the microneedle mould in a vacuum environment, recovering the redundant needle body solution, and drying;
(3) preparation of the substrate: dispersing a polymer matrix material into pure water, wherein the mass ratio of the polymer matrix material to the pure water is 1:10, adding the polymer matrix material into the mold treated in the step (2), completely filling the needle body solution into the gaps of the microneedle mold in a vacuum environment, recovering the redundant needle body solution, drying and demolding to obtain the soluble microneedle patch for relieving itching and diminishing swelling.
The invention has the beneficial effects that: compared with the prior art, the microneedle patch for skin itching-relieving and anti-allergic treatment provided by the invention can realize efficient micro-dosage transdermal administration compared with other existing transdermal preparations, can be dissolved by itself after penetrating into human skin, and has the advantage of transdermal effect; compared with oral medicines, the invention realizes local administration, realizes micro administration, can achieve the effect by micro dose, realizes accurate striking and reduces the side effect of the whole body; the invention exceeds the administration efficiency of the conventional itching-relieving and anti-allergic transdermal preparation, and simultaneously, the preparation method of the biosoluble microneedle patch is simple and convenient and has strong operability.
Detailed Description
The following examples are given to further illustrate the present invention, but the examples are only for the purpose of illustration and not for the purpose of limitation, and therefore any simple modification of the present invention in the context of the method of the present invention is within the scope of the claims.
Example 1
The invention adopts an injection molding method to prepare the diphenhydramine soluble microneedle patch, firstly prepares a needle body solution, and then prepares the soluble microneedle patch by injection molding. The preparation process of the soluble microneedle patch specifically comprises the following steps:
(1) uniformly dispersing 0.05mg of diphenhydramine hydrochloride and 475mg of sodium hyaluronate (15KD) into 1mL of pure water, and adjusting the pH to 6.8 by using hydrochloric acid to obtain a needle body solution;
(2) adding the needle body solution prepared in the step (1) into a commercially available microneedle mould, completely filling the needle body solution into the gap of the microneedle mould in a vacuum environment, recovering the redundant needle body solution, and drying;
(3) and (3) dispersing 300mg of sodium hyaluronate (15KD) into 3mL of pure water, adding the pure water into the mold treated in the step (2), completely filling the needle body solution into the gap of the microneedle mold in a vacuum environment, recovering the redundant needle body solution, drying and demolding to obtain the soluble microneedle patch for relieving itching and diminishing swelling.
Example 2
The invention adopts an injection molding method to prepare the chlorpheniramine soluble microneedle patch, firstly prepares a needle body solution, and then prepares the soluble microneedle patch by injection molding. The preparation process of the soluble microneedle patch specifically comprises the following steps:
(1) uniformly dispersing 0.07mg of chlorpheniramine hydrochloride and 475mg of polyvinyl alcohol (15KD) into 2.5mL of pure water, and using hydrochloric acid to adjust the pH value to 7.0 to obtain a needle body solution;
(2) adding the needle body solution prepared in the step (1) into a commercially available microneedle mould, completely filling the needle body solution into the gap of the microneedle mould in a vacuum environment, recovering the redundant needle body solution, and drying;
(3) and (3) dispersing 300mg of polyvinyl alcohol (15KD) into 3mL of pure water, adding the pure water into the mold treated in the step (2), completely filling the needle body solution into the gap of the microneedle mold in a vacuum environment, recovering the redundant needle body solution, drying and demolding to obtain the soluble microneedle patch for relieving itching and diminishing swelling.
Example 3
The invention adopts an injection molding method to prepare the loratadine soluble microneedle patch, and the soluble microneedle patch can be prepared by preparing a needle body solution and then performing injection molding. The preparation process of the soluble microneedle patch specifically comprises the following steps:
(1) uniformly dispersing 0.10mg of loratadine hydrochloride and 475mg of chondroitin sulfate (15KD) into 7.5mL of pure water, and using hydrochloric acid to adjust the pH value to 7.1 to obtain a needle body solution;
(2) adding the needle body solution prepared in the step (1) into a commercially available microneedle mould, completely filling the needle body solution into the gap of the microneedle mould in a vacuum environment, recovering the redundant needle body solution, and drying;
(3) and (3) dispersing 300mg of chondroitin sulfate (15KD) into 3mL of pure water, adding the solution into the mold treated in the step (2), completely filling the needle body solution into the gap of the microneedle mold in a vacuum environment, recovering the redundant needle body solution, drying and demolding to obtain the soluble microneedle patch for relieving itching and diminishing swelling.
Example 4
The invention adopts an injection molding method to prepare the loratadine soluble microneedle patch, and the soluble microneedle patch can be prepared by preparing a needle body solution and then performing injection molding. The preparation process of the soluble microneedle patch specifically comprises the following steps:
(1) uniformly dispersing 25mg of cetirizine and 480mg of polyvinylpyrrolidone (15KD) into 7.5mL of pure water, and using hydrochloric acid to adjust the pH value to 7.1 to obtain a needle body solution;
(2) adding the needle body solution prepared in the step (1) into a commercially available microneedle mould, completely filling the needle body solution into the gap of the microneedle mould in a vacuum environment, recovering the redundant needle body solution, and drying;
(3) and (3) dispersing 200mg of polyvinylpyrrolidone (15KD) into 2mL of pure water, adding the pure water into the mold treated in the step (2), completely filling the needle body solution into the gaps of the microneedle mold in a vacuum environment, recovering the redundant needle body solution, drying and demolding to obtain the soluble microneedle patch for relieving itching and diminishing swelling.
Example 5
The invention adopts an injection molding method to prepare the loratadine soluble microneedle patch, and the soluble microneedle patch can be prepared by preparing a needle body solution and then performing injection molding. The preparation process of the soluble microneedle patch specifically comprises the following steps:
(1) uniformly dispersing 10mg of cetirizine and 485mg of chitosan (15KD) into 7.5mL of pure water, and using hydrochloric acid to adjust the pH value to 7.1 to obtain a needle body solution;
(2) adding the needle body solution prepared in the step (1) into a commercially available microneedle mould, completely filling the needle body solution into the gap of the microneedle mould in a vacuum environment, recovering the redundant needle body solution, and drying;
(3) and (3) dispersing 200mg of chitosan (15KD) into 2mL of pure water, adding the pure water into the mold treated in the step (2), completely filling the needle body solution into the gaps of the microneedle mold in a vacuum environment, recovering the redundant needle body solution, drying and demolding to obtain the soluble microneedle patch for relieving itching and diminishing swelling.
Furthermore, chlorpheniramine, diphenhydramine, loratadine, cetirizine, chlorpheniramine, flufenamate butyl ester and ethofesalamine or medically acceptable salts of the above medicines belong to antihistamine medicines and can be replaced mutually.
Furthermore, the desonide, dexamethasone acetate, the hydrocortisone, the fluticasone propionate, the halomethasone and the halcinonide or medically acceptable salts of the medicines belong to glucocorticoid medicines and can be mutually replaced.
Example 6
(1) In this example, the in vivo pharmacodynamics of the soluble microneedle patch for skin itching-relieving and antiallergic treatment prepared in example 2 was studied. The preparation of the reagent was carried out according to the preparation method of example 2.
(2) Animal grouping, modeling and dosing regimen
40 mice were randomly divided into 4 groups of 10 mice each with male and female halves, each group consisting of a model control group, a positive drug group, an example 2 group, and a blank group, according to sex and body weight. 24h before molding, mice in each group were shaved at the back of the right neck (about 2cm by 3 cm). Blank group and model group are not processed; the positive group was given 0.3g of compound dexamethasone cream spread, and the example 2 group was given microneedle patch pressed (0.5 μ g diphenhydramine hydrochloride/100 g body weight). The histamine itch evaluation model adopts a 4-aminopyridine (4-AP) mouse itch model. After 10min after administration, 4-AP solution (0.01%, diluted with physiological saline) was injected under the skin at the back of the neck of the mice in the model control group, the positive drug group, and the example 2 group.
(3) Observation and recording of mouse itching times
After injection of 4-aminopyridine, they were placed in observation cages and the mice were scored for licking within 10min, and the mice were scored for scratching, with a pause after continued scratching, and counted 1 time.
(4) Detection of serum factors
And (3) immediately anaesthetizing after the recording in the step (3) is finished, taking 0.4mL of blood from the orbit, standing the blood for layering, centrifuging the blood for 4min at the speed of 2500r/min to prepare serum, and storing the serum at the temperature of minus 25 ℃ for later use. The concentrations of IL-31, PAF and 5-HT in the serum were determined by ELISA.
(5) Determination of amine content in skin tissue
Taking 0.3g of skin around the injection site, sucking water by using filter paper, crushing, grinding into powder in liquid nitrogen, adding 5mL of PBS buffer (0.01mol/L, pH 7.4), centrifuging at 4500r/min for 15min, taking supernatant, and detecting the content of histamine in the supernatant by ELISA method.
The results of the behavioural study are shown in table 1, compared with the model group, the mice in the example 2 group all have obviously reduced pruritus times within 10min (P <0.05), and compared with the positive group (smearing medicine), the mice in the example 2 group have obvious advantages in treatment effect, and the mice in the surface example 2 have obvious advantages in itching relieving effect. The invention has better transdermal advantage.
Table 1: results of the mouse scratching ethology
| Group of | Number of animals | Number of itching within 10min |
| Blank group | 10 | 0.8±0.18 |
| Model set | 10 | 28±3.78 |
| Positive group | 10 | 19±2.47 |
| EXAMPLE 2 group | 10 | 9.48±3.40 |
The results of histamine are shown in table 2, which shows that the mass concentration of histamine in mice in the positive control group and the example 2 group is significantly reduced compared to the model group (P <0.05), and the reduction of histamine in mice in the example 2 group is extremely significant (P < 0.01). The experimental result shows that the group in the example 2 has the function of remarkably antagonizing the production of histamine so as to play the role of relieving itching, and the histamine antagonizing capability of the group is stronger than that of the positive medicament compound dexamethasone emulsifiable paste. The invention has better transdermal advantage.
Table 2: results of mouse histamine content determination
| Group of | Number of animals | Histamine content/. mu.g/L |
| Blank group | 10 | 16.28±1.24 |
| Model set | 10 | 26.22±1.58 |
| Positive group | 10 | 22.54±3.40 |
| EXAMPLE 2 group | 10 | 17.23±1.53 |
IL-31 plays an important role in allergic diseases. PAF is a lipid mediator with strong proinflammatory activity, can activate mast cells and release platelets, and then causes the skin mast cells to release histamine, 5-HT and other vasoactive amines, so that pruritus and vascular changes are caused, and the pruritus and the vascular changes are caused. The results (Table 3) show that the mass concentrations of IL-31, PAF and 5-HT in the serum of the mice in the positive group and the 1, 8-cineole group are remarkably reduced compared with the model group (P < 0.01). The mass concentration of PAF in the serum of mice in the positive control group and the example 2 group is obviously reduced compared with the model group (P < 0.01). This indicates that the present invention has a superior transdermal benefit.
Table 3: results of mouse histamine content determination
| Group of | Number of animals | IL-31/μg/L | PAF/μg/L | 5-HT/μg/L |
| Blank group | 10 | 22.28±0.26 | 76.32±0.27 | 174.66±1.58 |
| Model set | 10 | 23.27±0.64 | 82.26±0.94 | 195.62±4.26 |
| Positive group | 10 | 22.21±0.57 | 75.21±0.33 | 158.55±0.59 |
| EXAMPLE 2 group | 10 | 22.14±0.51 | 72.19±0.94 | 143.58±0.81 |
In conclusion, compared with other existing transdermal preparations, the microneedle patch for skin itching-relieving and anti-allergic treatment provided by the invention can realize efficient micro-dosage transdermal administration and has the advantage of transdermal effect; compared with oral medicines, the invention realizes local administration, realizes micro administration, can achieve the effect by micro dose, realizes accurate striking and reduces the side effect of the whole body; the invention exceeds the administration efficiency of the conventional itching-relieving and anti-allergic transdermal preparation, and simultaneously, the preparation method of the biosoluble microneedle patch is simple and convenient and has strong operability.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. It will be readily apparent to those skilled in the art that various modifications to these embodiments and the generic principles defined herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments. Those skilled in the art should appreciate that many modifications and variations are possible in light of the above teaching without departing from the scope of the invention.
Claims (6)
1. A soluble microneedle patch for itching relieving and anti-allergic treatment of skin is characterized by comprising a substrate and a needle body, wherein the needle body is prepared by mixing an active drug, a polymer matrix material and pure water, and the mass ratio of the active drug to the polymer matrix material to the pure water is 0.01-5:95-99.99: 200-; the substrate is prepared from a high-molecular matrix material.
2. The dissolvable microneedle patch for antipruritic and detumescence therapy according to claim 1, wherein said active pharmaceutical ingredient is an antihistamine or a glucocorticoid.
3. The soluble microneedle patch for antipruritic and repercussive therapy according to claim 2, wherein said antihistamine is preferably one or more of chlorpheniramine, diphenhydramine, loratadine, cetirizine, chlorpheniramine, flufenamic acid butyl ester, ethoxybenzene salicylamine or a pharmaceutically acceptable salt of the above antihistamine in a mixture in any ratio.
4. The soluble microneedle patch for antipruritic and detumescence therapy according to claim 2, wherein the glucocorticoid is preferably one or more of desonide, dexamethasone acetate, chlordiazepoxide, fluticasone propionate, halomethasone cream, halcinonide or a medically acceptable salt thereof in any ratio.
5. The soluble microneedle patch for antipruritic and detumescence therapy according to claim 1, wherein the polymer matrix material is preferably one or more of polyvinylpyrrolidone, polyvinyl alcohol, chitosan, sodium hyaluronate, chondroitin sulfate and modified derivatives thereof mixed at any ratio.
6. The method for preparing a dissolvable microneedle patch for antipruritic and antiallergic treatments for skin according to any one of claims 1 to 5, comprising the steps of:
(1) preparing a needle body material: uniformly dispersing active medicine components and a high-molecular matrix material into pure water, wherein the mass ratio of the active medicine to the high-molecular matrix material to the pure water is 0.01-5:95-99.99:200 and 1500, and adjusting the pH to 7.0 +/-0.2 by using an acid-base regulator to obtain a needle body solution;
(2) preparing a needle body: adding the needle body solution prepared in the step (1) into a microneedle mould, completely filling the needle body solution into the gap of the microneedle mould in a vacuum environment, recovering the redundant needle body solution, and drying;
(3) preparation of the substrate: dispersing a polymer matrix material into pure water, wherein the mass ratio of the polymer matrix material to the pure water is 1:10, adding the polymer matrix material into the mold treated in the step (2), completely filling the needle body solution into the gaps of the microneedle mold in a vacuum environment, recovering the redundant needle body solution, drying and demolding to obtain the soluble microneedle patch for relieving itching and diminishing swelling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111152261.1A CN113679658A (en) | 2021-09-29 | 2021-09-29 | Soluble microneedle patch for itching-relieving and anti-allergic treatment of skin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111152261.1A CN113679658A (en) | 2021-09-29 | 2021-09-29 | Soluble microneedle patch for itching-relieving and anti-allergic treatment of skin and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113679658A true CN113679658A (en) | 2021-11-23 |
Family
ID=78587348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111152261.1A Pending CN113679658A (en) | 2021-09-29 | 2021-09-29 | Soluble microneedle patch for itching-relieving and anti-allergic treatment of skin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113679658A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522136A (en) * | 2022-02-21 | 2022-05-24 | 深圳玉莱漫生物科技有限公司 | Transdermal drug delivery microneedle capable of effectively protecting drug activity |
| CN114732800A (en) * | 2022-04-07 | 2022-07-12 | 温州医科大学附属第一医院 | Preparation method of inflammation-responsive microneedle patch for atopic dermatitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170124322A (en) * | 2016-05-02 | 2017-11-10 | 주식회사 엘지생활건강 | Soluble microneedle patch for delivery of antiallergic drugs |
| CN113274372A (en) * | 2021-05-17 | 2021-08-20 | 长春工业大学 | Preparation method of microneedle patch for quickly and efficiently relieving itching due to mosquito bites |
-
2021
- 2021-09-29 CN CN202111152261.1A patent/CN113679658A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170124322A (en) * | 2016-05-02 | 2017-11-10 | 주식회사 엘지생활건강 | Soluble microneedle patch for delivery of antiallergic drugs |
| CN113274372A (en) * | 2021-05-17 | 2021-08-20 | 长春工业大学 | Preparation method of microneedle patch for quickly and efficiently relieving itching due to mosquito bites |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522136A (en) * | 2022-02-21 | 2022-05-24 | 深圳玉莱漫生物科技有限公司 | Transdermal drug delivery microneedle capable of effectively protecting drug activity |
| CN114732800A (en) * | 2022-04-07 | 2022-07-12 | 温州医科大学附属第一医院 | Preparation method of inflammation-responsive microneedle patch for atopic dermatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7001609B1 (en) | Mucosal originated drug delivery systems and animal applications | |
| CN113679658A (en) | Soluble microneedle patch for itching-relieving and anti-allergic treatment of skin and preparation method thereof | |
| US20230285313A1 (en) | Pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site | |
| AU768040B2 (en) | Mucosal originated drug delivery systems and animal applications | |
| US20240082175A1 (en) | Cannabinoid and menthol transdermal delivery systems and methods | |
| CN109820824A (en) | A kind of capsaicine liquid crystal nano-spray preparation and preparation method thereof for promoting skin wound healing | |
| JP7190571B2 (en) | Uses of Bray Aconitine A | |
| AU2014241396A1 (en) | Method of treating infections, diseases or disorders of nail unit | |
| CN102133175B (en) | Amygdalin gel and preparation method and medicinal application thereof | |
| Benson et al. | Challenges and Innovations of Controlled Drug Delivery | |
| CN110193017B (en) | Film spraying agent for promoting hair growth and preparation method thereof | |
| KR100910848B1 (en) | Microsphere for nasal spray comprising drug for treating allergic rhinitis and preparation method thereof | |
| US20200315986A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| CN112206281A (en) | Anti-infection wound repair pharmaceutical composition, preparation method and application thereof | |
| AU2015349153B2 (en) | Application of levalbuterol formulation in treatment of skin and mucous membrane traumatic ulcers | |
| Nuttall | Management of atopic dermatitis | |
| CN112915084B (en) | Pharmaceutical composition for treating senile cutaneous pruritus and external preparation | |
| CN114681474B (en) | Composition with detumescence and antipruritic effects | |
| CN115715763B (en) | Bromhexine hydrochloride solid microsphere and preparation method thereof | |
| CN115068406A (en) | Apremilast gel for treating alopecia areata and preparation process thereof | |
| RU2426540C1 (en) | Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition | |
| WO2017085262A1 (en) | A pharmaceutical film composition having improved residence time on the application site | |
| CN117815399A (en) | Composition for treating atopic dermatitis, preparation method and application thereof | |
| CN114209643A (en) | Medicine for treating infantile asthma | |
| CN113332234A (en) | Formula of tranilast emulsifiable paste and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |